Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors
作者:Christopher J. Bungard、Peter D. Williams、Jurgen Schulz、Catherine M. Wiscount、M. Katharine Holloway、H. Marie Loughran、Jesse J. Manikowski、Hua-Poo Su、David J. Bennett、Lehua Chang、Xin-Jie Chu、Alejandro Crespo、Michael P. Dwyer、Kartik Keertikar、Gregori J. Morriello、Andrew W. Stamford、Sherman T. Waddell、Bin Zhong、Bin Hu、Tao Ji、Tracy L. Diamond、Carolyn Bahnck-Teets、Steven S. Carroll、John F. Fay、Xu Min、William Morris、Jeanine E. Ballard、Michael D. Miller、John A. McCauley
DOI:10.1021/acsmedchemlett.7b00386
日期:2017.12.14
Using the HIV-1 protease binding mode of MK-8718 and PL-100 as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core showed an 60-fold increase in enzyme binding affinity and a 10-fold increase in antiviral activity relative to MK-8718.
以MK-8718和PL-100的HIV-1蛋白酶结合模式为灵感,设计并合成了一种新型的天冬氨酸结合双环哌嗪磺酰胺核心。相对于MK-8718,所得的含有该核心的HIV-1蛋白酶抑制剂显示出酶结合亲和力增加了60倍,抗病毒活性增加了10倍。